In April 2022, HOPA submitted a proposal to the Board of Pharmacy Specialties to continue to provide professional development programs for the recertification of board-certified pharmacists. With BPS's approval, HOPA is proud to provide Board Certified Oncology Pharmacy (BCOP) continuing education for another seven years. The new contract begins January 1, 2024 and runs through December 31, 2030.

Read the announcement: BPS Announces Professional Development Programs Approved for the Recertification of Board-Certified Pharmacists beginning in January 2024

HOPA Provides at Least 60 BCOP CEs Each Year

Each year, HOPA provides at least 60 BCOP Continuing Education Credits for members and other board certified hematology/oncology pharmacists. Explore the latest BCOP Updates and BCOP Self-Study Releases and more!

Tools and Resources Late Breaking News

Related Articles

Read all latest news Right Pointing Arrow
An image of a doctor looking at an x-ray of lungs with cancer
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Zongertinib

January 12, 2026

Reyam Katchi, PharmD, PGY2 Hematology/Oncology Pharmacy Resident, and Kiera Roubal, PharmD, Oncology Clinical Pharmacist, break down the potential role for zongertinib in the treatment of non-squamous NSCLC with HER2 TKD activating mutations.

A graphic of a man's lungs on a blue background
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Taletrectinib

January 12, 2026

Benjamin Pastore, PharmD, PGY2 Adult Oncology Pharmacy Resident, and Jasmine Patel, PharmD, BCOP, Clinical Pharmacy Specialist - Thoracic Oncology, discuss the potential role of taletrectinib in the treatment of metastatic non-small cell lung cancer.

A line of women with breast cancer ribbons on their chests
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Imlunestrant

January 08, 2026

Chan Tae Park, PharmD, PGY1 Pharmacy Resident, and Andrew Li, PharmD, BCOP, Oncology Pharmacist, dig into the potential role of imlunestrant (Inluriyo) in treating ESR1-mutated advanced/metastatic ER+, HER2- breast cancer.